Last reviewed · How we verify

MU-JHU CARE — Portfolio Competitive Intelligence Brief

MU-JHU CARE pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Long-acting Cabotegravir injection Long-acting Cabotegravir injection marketed Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease / Virology
TDF/3TC/EFV or DTG or NVP TDF/3TC/EFV or DTG or NVP marketed Antiretroviral combination therapy (NRTI + NNRTI or INSTI) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ANRS, Emerging Infectious Diseases · 1 shared drug class
  2. Abbott · 1 shared drug class
  3. Desmond Tutu HIV Foundation · 1 shared drug class
  4. Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · 1 shared drug class
  5. Germans Trias i Pujol Hospital · 1 shared drug class
  6. Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux · 1 shared drug class
  7. Massachusetts General Hospital · 1 shared drug class
  8. Merck Sharp & Dohme LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MU-JHU CARE:

Cite this brief

Drug Landscape (2026). MU-JHU CARE — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mu-jhu-care. Accessed 2026-05-16.

Related